{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T01:11:06Z","timestamp":1789089066174,"version":"build-2803163510"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02338-6","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:52:16Z","timestamp":1778903536000},"page":"1091-1101","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors"],"prefix":"10.1007","volume":"86","author":[{"given":"Michael J.","family":"Chehade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5789-5306","authenticated-orcid":false,"given":"Michael J.","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshag D.","family":"Mooradian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"9","key":"2338_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9091083","volume":"9","author":"B Franczyk","year":"2021","unstructured":"Franczyk B, Rysz J, \u0141awi\u0144ski J, Rysz-G\u00f3rzy\u0144ska M, Gluba-Brz\u00f3zka A. Is a high HDL-cholesterol level always beneficial? Biomedicines. 2021;9(9):1083. https:\/\/doi.org\/10.3390\/biomedicines9091083.","journal-title":"Biomedicines"},{"issue":"7897","key":"2338_CR2","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S0140-6736(75)92376-4","volume":"305","author":"GJ Miller","year":"1975","unstructured":"Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of isch\u00e6mic heart-disease. Lancet. 1975;305(7897):16\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(75)92376-4.","journal-title":"Lancet"},{"issue":"9921","key":"2338_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61752-3","volume":"383","author":"SS Mahmood","year":"2013","unstructured":"Mahmood SS, Levy D, Vasan RS, Wang TJ. The Framingham Heart Study and the epidemiology of cardiovascular diseases: a historical perspective. Lancet. 2013;383(9921):999. https:\/\/doi.org\/10.1016\/S0140-6736(13)61752-3.","journal-title":"Lancet"},{"issue":"9841","key":"2338_CR4","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. Lancet. 2012;380(9841):572\u201380. https:\/\/doi.org\/10.1016\/S0140-6736(12)60312-2.","journal-title":"Lancet"},{"key":"2338_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2025.1713387","volume":"12","author":"FW Ouyang","year":"2025","unstructured":"Ouyang FW, Chiang HH, Hsu WL, et al. Dysfunctional high-density lipoprotein: an updated review. Front Cardiovasc Med. 2025;12:1713387. https:\/\/doi.org\/10.3389\/fcvm.2025.1713387.","journal-title":"Front Cardiovasc Med"},{"issue":"Suppl","key":"2338_CR6","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R800088-JLR200","volume":"50","author":"DJ Rader","year":"2009","unstructured":"Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res. 2009;50(Suppl):S189. https:\/\/doi.org\/10.1194\/jlr.R800088-JLR200.","journal-title":"J Lipid Res"},{"issue":"10","key":"2338_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.119.312617","volume":"124","author":"M Ouimet","year":"2019","unstructured":"Ouimet M, Barrett TJ, Fisher EA. HDL and reverse cholesterol transport: basic mechanisms and their roles in vascular health and disease. Circ Res. 2019;124(10):1505. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.312617.","journal-title":"Circ Res"},{"issue":"3","key":"2338_CR8","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s12013-022-01081-5","volume":"80","author":"AD Dergunov","year":"2022","unstructured":"Dergunov AD, Baserova VB. Different pathways of cellular cholesterol efflux. Cell Biochem Biophys. 2022;80(3):471\u201381. https:\/\/doi.org\/10.1007\/s12013-022-01081-5.","journal-title":"Cell Biochem Biophys"},{"issue":"6","key":"2338_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/biof.1187","volume":"40","author":"S Wang","year":"2014","unstructured":"Wang S, Smith JD. ABCA1 and nascent HDL biogenesis. BioFactors. 2014;40(6):547. https:\/\/doi.org\/10.1002\/biof.1187.","journal-title":"BioFactors"},{"key":"2338_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-90-481-8622-8_7","volume":"51","author":"S Lund-Katz","year":"2010","unstructured":"Lund-Katz S, Phillips MC. High density lipoprotein structure\u2013function and role in reverse cholesterol transport. Subcell Biochem. 2010;51:183. https:\/\/doi.org\/10.1007\/978-90-481-8622-8_7.","journal-title":"Subcell Biochem"},{"issue":"10","key":"2338_CR11","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1007\/s40265-022-01743-x","volume":"82","author":"MJ Haas","year":"2022","unstructured":"Haas MJ, Mooradian AD. Potential therapeutic agents that target ATP Binding Cassette A1 (ABCA1) gene expression. Drugs. 2022;82(10):1055\u201375. https:\/\/doi.org\/10.1007\/s40265-022-01743-x.","journal-title":"Drugs"},{"issue":"2","key":"2338_CR12","doi-asserted-by":"publisher","DOI":"10.14744\/AnatolJCardiol.2017.7608","volume":"18","author":"KT Trajkovska","year":"2017","unstructured":"Trajkovska KT, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol. 2017;18(2):149. https:\/\/doi.org\/10.14744\/AnatolJCardiol.2017.7608.","journal-title":"Anatol J Cardiol"},{"issue":"7","key":"2338_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s40265-015-0390-1","volume":"75","author":"AD Mooradian","year":"2015","unstructured":"Mooradian AD, Haas MJ. Targeting high-density lipoproteins: increasing de novo production versus decreasing clearance. Drugs. 2015;75(7):713\u201322. https:\/\/doi.org\/10.1007\/s40265-015-0390-1.","journal-title":"Drugs"},{"issue":"7","key":"2338_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9070836","volume":"9","author":"KT Lappeg\u00e5rd","year":"2021","unstructured":"Lappeg\u00e5rd KT, Kjellmo CA, Hovland A. High-density lipoprotein subfractions: much ado about nothing or clinically important? Biomedicines. 2021;9(7):836. https:\/\/doi.org\/10.3390\/biomedicines9070836.","journal-title":"Biomedicines"},{"issue":"14","key":"2338_CR15","doi-asserted-by":"publisher","first-page":"7856","DOI":"10.3390\/ijms25147856","volume":"25","author":"Q Chen","year":"2024","unstructured":"Chen Q, Abudukeremu A, Li K, et al. High-density lipoprotein subclasses and their role in the prevention and treatment of cardiovascular disease: a narrative review. Int J Mol Sci. 2024;25(14):7856. https:\/\/doi.org\/10.3390\/ijms25147856.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2338_CR16","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.jacl.2012.03.001","volume":"6","author":"HR Superko","year":"2012","unstructured":"Superko HR, Pendyala L, Williams PT, Momary KM, King SB, Garrett BC. High-density lipoprotein subclasses and their relationship to cardiovascular disease. J Clin Lipidol. 2012;6(6):496\u2013523. https:\/\/doi.org\/10.1016\/j.jacl.2012.03.001.","journal-title":"J Clin Lipidol"},{"issue":"8","key":"2338_CR17","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R034025","volume":"54","author":"MC Phillips","year":"2013","unstructured":"Phillips MC. New insights into the determination of HDL structure by apolipoproteins. J Lipid Res. 2013;54(8):2034. https:\/\/doi.org\/10.1194\/jlr.R034025.","journal-title":"J Lipid Res"},{"issue":"JAN","key":"2338_CR18","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3389\/fphar.2017.00989","volume":"8","author":"NJ Woudberg","year":"2018","unstructured":"Woudberg NJ, Pedretti S, Lecour S, et al. Pharmacological intervention to modulate HDL: what do we target? Front Pharmacol. 2018;8(JAN):989. https:\/\/doi.org\/10.3389\/fphar.2017.00989.","journal-title":"Front Pharmacol"},{"key":"2338_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113634","author":"AS Bhale","year":"2022","unstructured":"Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: structure, function, mutations, and potential therapeutics. Biomed Pharmacother. 2022. https:\/\/doi.org\/10.1016\/j.biopha.2022.113634.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2338_CR20","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1002\/dmrr.1057","volume":"26","author":"MJ Haas","year":"2010","unstructured":"Haas MJ, Mooradian AD. Regulation of high-density lipoprotein by inflammatory cytokines: establishing links between immune dysfunction and cardiovascular disease. Diabetes Metab Res Rev. 2010;26(2):90\u20139. https:\/\/doi.org\/10.1002\/dmrr.1057.","journal-title":"Diabetes Metab Res Rev"},{"issue":"6","key":"2338_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-021-00925-4","volume":"23","author":"WS Davidson","year":"2021","unstructured":"Davidson WS, Cooke AL, Swertfeger DK, Shah AS. The difference between high density lipoprotein subfractions and subspecies: an evolving model in cardiovascular disease and diabetes. Curr Atheroscler Rep. 2021;23(6):23. https:\/\/doi.org\/10.1007\/s11883-021-00925-4.","journal-title":"Curr Atheroscler Rep"},{"issue":"3","key":"2338_CR22","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1194\/jlr.M500281-JLR200","volume":"47","author":"MCB Garin","year":"2006","unstructured":"Garin MCB, Moren X, James RW. Paraoxonase-1 and serum concentrations of HDL-cholesterol and apoA-I. J Lipid Res. 2006;47(3):515\u201320. https:\/\/doi.org\/10.1194\/jlr.M500281-JLR200.","journal-title":"J Lipid Res"},{"key":"2338_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1476-511X-10-70","author":"KM Argraves","year":"2011","unstructured":"Argraves KM, Sethi AA, Gazzolo PJ, et al. S1P, dihydro-S1P and C24:1-ceramide levels in the HDL-containing fraction of serum inversely correlate with occurrence of ischemic heart disease. Lipids Health Dis. 2011. https:\/\/doi.org\/10.1186\/1476-511X-10-70.","journal-title":"Lipids Health Dis"},{"issue":"Pt 3","key":"2338_CR24","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1042\/0264-6021:3520809","volume":"352","author":"N Murata","year":"2000","unstructured":"Murata N, Sato K, Kon J, et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J. 2000;352(Pt 3):809. https:\/\/doi.org\/10.1042\/0264-6021:3520809.","journal-title":"Biochem J"},{"issue":"4","key":"2338_CR25","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1172\/jci18004","volume":"113","author":"JR Nofer","year":"2004","unstructured":"Nofer JR, van der Giet M, T\u00f6lle M, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113(4):569\u201381. https:\/\/doi.org\/10.1172\/jci18004.","journal-title":"J Clin Invest"},{"issue":"6","key":"2338_CR26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11883-021-00925-4","volume":"23","author":"WS Davidson","year":"2021","unstructured":"Davidson WS, Cooke AL, Swertfeger DK, Shah AS. The difference between high density lipoprotein subfractions and subspecies: an evolving model in cardiovascular disease and diabetes. Curr Atheroscler Rep. 2021;23(6):23. https:\/\/doi.org\/10.1007\/s11883-021-00925-4.","journal-title":"Curr Atheroscler Rep"},{"issue":"11","key":"2338_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112233","volume":"10","author":"I Bonilha","year":"2021","unstructured":"Bonilha I, Zimetti F, Zanotti I, Papotti B, Sposito AC. Dysfunctional high-density lipoproteins in type 2 diabetes mellitus: molecular mechanisms and therapeutic implications. J Clin Med. 2021;10(11):2233. https:\/\/doi.org\/10.3390\/jcm10112233.","journal-title":"J Clin Med"},{"issue":"2","key":"2338_CR28","doi-asserted-by":"publisher","first-page":"601","DOI":"10.3390\/ijms21020601","volume":"21","author":"J Rysz","year":"2020","unstructured":"Rysz J, Gluba-Brz\u00f3zka A, Rysz-G\u00f3rzy\u0144ska M, Franczyk B. The role and function of HDL in patients with chronic kidney disease and the risk of cardiovascular disease. Int J Mol Sci. 2020;21(2):601. https:\/\/doi.org\/10.3390\/ijms21020601.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2338_CR29","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s40265-020-01265-4","volume":"80","author":"JJ Feghaly","year":"2020","unstructured":"Feghaly JJ, Mooradian AD. The rise and fall \u201cing\u201d of the HDL hypothesis. Drugs. 2020;80(4):353\u201362. https:\/\/doi.org\/10.1007\/s40265-020-01265-4.","journal-title":"Drugs"},{"issue":"10","key":"2338_CR30","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.3390\/ph15101278","volume":"15","author":"V Vyletelov\u00e1","year":"2022","unstructured":"Vyletelov\u00e1 V, Nov\u00e1kov\u00e1 M, Pa\u0161kov\u00e1 \u013d. Alterations of HDL\u2019s to piHDL\u2019s proteome in patients with chronic inflammatory diseases, and HDL-targeted therapies. Pharm Basel. 2022;15(10):1278. https:\/\/doi.org\/10.3390\/ph15101278.","journal-title":"Pharm Basel"},{"issue":"2","key":"2338_CR31","first-page":"150","volume":"41","author":"C Palacio","year":"2011","unstructured":"Palacio C, Alexandraki I, Bertholf RL, Mooradian AD. Transient dyslipidemia mimicking the plasma lipid profile of Tangier disease in a diabetic patient with gram negative sepsis. Ann Clin Lab Sci. 2011;41(2):150\u20133.","journal-title":"Ann Clin Lab Sci"},{"issue":"6","key":"2338_CR32","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1007\/s00223-015-0106-2","volume":"98","author":"KR Wehmeier","year":"2016","unstructured":"Wehmeier KR, Kurban W, Chandrasekharan C, Onstead-Haas L, Mooradian AD, Haas MJ. Inhibition of ABCA1 protein expression and cholesterol efflux by TNF \u03b1 in MLO-Y4 osteocytes. Calcif Tissue Int. 2016;98(6):586\u201395. https:\/\/doi.org\/10.1007\/s00223-015-0106-2.","journal-title":"Calcif Tissue Int"},{"issue":"7","key":"2338_CR33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1001\/jamacardio.2022.0912","volume":"7","author":"C Liu","year":"2022","unstructured":"Liu C, Dhindsa D, Almuwaqqat Z, et al. Association between high-density lipoprotein cholesterol levels and adverse cardiovascular outcomes in high-risk populations. JAMA Cardiol. 2022;7(7):672\u201380. https:\/\/doi.org\/10.1001\/jamacardio.2022.0912.","journal-title":"JAMA Cardiol."},{"issue":"20","key":"2338_CR34","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1161\/CIR.0b013e3182160726","volume":"123","author":"M Miller","year":"2011","unstructured":"Miller M, Stone NJ, Ballantyne C, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123(20):2292\u2013333. https:\/\/doi.org\/10.1161\/CIR.0b013e3182160726.","journal-title":"Circulation"},{"issue":"9","key":"2338_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1007\/s00392-017-1106-1","volume":"106","author":"W M\u00e4rz","year":"2017","unstructured":"M\u00e4rz W, Kleber ME, Scharnagl H, et al. HDL cholesterol: reappraisal of its clinical relevance. Clin Res Cardiol. 2017;106(9):663\u2013663. https:\/\/doi.org\/10.1007\/s00392-017-1106-1.","journal-title":"Clin Res Cardiol"},{"issue":"1","key":"2338_CR36","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/ATVBAHA.119.313381","volume":"40","author":"M Trinder","year":"2019","unstructured":"Trinder M, Walley KR, Boyd JH, Brunham LR. Causal inference for genetically determined levels of high-density lipoprotein cholesterol and risk of infectious disease. Arterioscler Thromb Vasc Biol. 2019;40(1):267\u2013267. https:\/\/doi.org\/10.1161\/ATVBAHA.119.313381.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"32","key":"2338_CR37","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459. https:\/\/doi.org\/10.1093\/eurheartj\/ehx144.","journal-title":"Eur Heart J"},{"issue":"3","key":"2338_CR38","doi-asserted-by":"publisher","first-page":"280","DOI":"10.12997\/jla.2024.13.3.280","volume":"13","author":"DS Ko","year":"2024","unstructured":"Ko DS, Kim YH. Mendelian randomization studies in atherosclerotic cardiovascular diseases. J Lipid Atheroscler. 2024;13(3):280\u201391. https:\/\/doi.org\/10.12997\/jla.2024.13.3.280.","journal-title":"J Lipid Atheroscler"},{"issue":"1","key":"2338_CR39","doi-asserted-by":"publisher","first-page":"5640","DOI":"10.1038\/s41467-021-25703-3","volume":"12","author":"AF Schmidt","year":"2021","unstructured":"Schmidt AF, Hunt NB, Gordillo-Mara\u00f1\u00f3n M, et al. Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease. Nat Commun. 2021;12(1):5640. https:\/\/doi.org\/10.1038\/s41467-021-25703-3.","journal-title":"Nat Commun"},{"issue":"25","key":"2338_CR40","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/nejmoa1409065","volume":"371","author":"A Rohatgi","year":"2014","unstructured":"Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med. 2014;371(25):2383\u201393. https:\/\/doi.org\/10.1056\/nejmoa1409065.","journal-title":"N Engl J Med"},{"key":"2338_CR41","doi-asserted-by":"publisher","unstructured":"Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377(13):1217\u201327. https:\/\/doi.org\/10.1056\/nejmoa1706444.","DOI":"10.1056\/nejmoa1706444"},{"issue":"9","key":"2338_CR42","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1038\/nm.2937","volume":"18","author":"DJ Rader","year":"2012","unstructured":"Rader DJ, Tall AR. Is it time to revise the HDL cholesterol hypothesis? Nat Med. 2012;18(9):1344\u20136. https:\/\/doi.org\/10.1038\/nm.2937.","journal-title":"Nat Med"},{"issue":"1","key":"2338_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2017","unstructured":"Tall AR, Rader DJ. The trials and tribulations of CETP inhibitors. Circ Res. 2017;122(1):106\u2013106. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311978.","journal-title":"Circ Res"},{"issue":"3","key":"2338_CR44","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jacc.2005.09.042","volume":"47","author":"PJ Barter","year":"2006","unstructured":"Barter PJ, Kastelein JJP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol. 2006;47(3):492\u20139. https:\/\/doi.org\/10.1016\/j.jacc.2005.09.042.","journal-title":"J Am Coll Cardiol"},{"key":"2338_CR45","doi-asserted-by":"publisher","unstructured":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367. https:\/\/doi.org\/10.1056\/nejmoa1107579.","DOI":"10.1056\/nejmoa1107579"},{"issue":"22","key":"2338_CR46","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/nejmoa1206797","volume":"367","author":"GG Schwartz","year":"2012","unstructured":"Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367(22):2089\u201399. https:\/\/doi.org\/10.1056\/nejmoa1206797.","journal-title":"N Engl J Med"},{"issue":"20","key":"2338_CR47","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/nejmoa1609581","volume":"376","author":"AM Lincoff","year":"2017","unstructured":"Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med. 2017;376(20):1933\u201342. https:\/\/doi.org\/10.1056\/nejmoa1609581.","journal-title":"N Engl J Med"},{"issue":"3","key":"2338_CR48","doi-asserted-by":"publisher","first-page":"732","DOI":"10.3390\/ijms21030732","volume":"21","author":"S Ben-Aicha","year":"2020","unstructured":"Ben-Aicha S, Badimon L, Vilahur G. Advances in HDL: much more than lipid transporters. Int J Mol Sci. 2020;21(3):732\u2013732. https:\/\/doi.org\/10.3390\/ijms21030732.","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2338_CR49","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/nejmoa0706628","volume":"357","author":"PJ Barter","year":"2007","unstructured":"Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109\u201322. https:\/\/doi.org\/10.1056\/nejmoa0706628.","journal-title":"N Engl J Med"},{"key":"2338_CR50","doi-asserted-by":"publisher","first-page":"251","DOI":"10.2147\/DDDT.S34976","volume":"6","author":"RA Hegele","year":"2012","unstructured":"Hegele RA, Alyse SG. Cholesteryl ester transfer protein inhibitors for dyslipidemia: focus on dalcetrapib. Drug Des Dev Ther. 2012;6:251. https:\/\/doi.org\/10.2147\/DDDT.S34976.","journal-title":"Drug Des Dev Ther"},{"issue":"2","key":"2338_CR51","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1161\/CIRCGENETICS.114.000663","volume":"8","author":"JC Tardif","year":"2015","unstructured":"Tardif JC, Rhea\u00fame E, Lemieux Perreault LP, et al. Pharmacogenomic determinants of the cardiovascular effects of dalcetrapib. Circ Cardiovasc Genet. 2015;8(2):372\u201382. https:\/\/doi.org\/10.1161\/CIRCGENETICS.114.000663.","journal-title":"Circ Cardiovasc Genet"},{"issue":"14","key":"2338_CR52","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1080\/14656566.2017.1365838","volume":"18","author":"SA Doggrell","year":"2017","unstructured":"Doggrell SA. No cardiovascular benefit with evacetrapib\u2014is this the end of the road for the \u201ccetrapibs\u201d? Expert Opin Pharmacother. 2017;18(14):1439\u201342. https:\/\/doi.org\/10.1080\/14656566.2017.1365838.","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"2338_CR53","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamacardio.2018.0569","volume":"3","author":"SE Nissen","year":"2018","unstructured":"Nissen SE, Pillai SG, Nicholls SJ, et al. ADCY9 genetic variants and cardiovascular outcomes with evacetrapib in patients with high-risk vascular disease: a nested case-control study. JAMA Cardiol. 2018;3(5):401\u20138. https:\/\/doi.org\/10.1001\/jamacardio.2018.0569.","journal-title":"JAMA Cardiol."},{"issue":"8","key":"2338_CR54","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","volume":"28","author":"SJ Nicholls","year":"2022","unstructured":"Nicholls SJ, Ditmarsch M, Kastelein JJ, et al. Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial. Nat Med. 2022;28(8):1672\u20138. https:\/\/doi.org\/10.1038\/s41591-022-01936-7.","journal-title":"Nat Med"},{"issue":"1","key":"2338_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/nejmoa2415820","volume":"393","author":"SJ Nicholls","year":"2025","unstructured":"Nicholls SJ, Nelson AJ, Ditmarsch M, et al. Safety and efficacy of obicetrapib in patients at high cardiovascular risk. N Engl J Med. 2025;393(1):51\u201361. https:\/\/doi.org\/10.1056\/nejmoa2415820.","journal-title":"N Engl J Med"},{"issue":"10491","key":"2338_CR56","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/S0140-6736(25)00721-4","volume":"405","author":"A Sarraju","year":"2025","unstructured":"Sarraju A, Brennan D, Hayden K, et al. Fixed-dose combination of obicetrapib and ezetimibe for LDL cholesterol reduction (TANDEM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2025;405(10491):1757\u201368. https:\/\/doi.org\/10.1016\/S0140-6736(25)00721-4.","journal-title":"Lancet"},{"issue":"0","key":"2338_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/J.JLR.2026.101028","volume":"0","author":"JA Inia","year":"2026","unstructured":"Inia JA, Zhang LH, Keijzer N, et al. Obicetrapib and ezetimibe enhance LDL receptor-mediated VLDL-clearance and regress atherosclerosis on atorvastatin background. J Lipid Res. 2026;0(0):101028. https:\/\/doi.org\/10.1016\/J.JLR.2026.101028.","journal-title":"J Lipid Res"},{"key":"2338_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2026.02.018","author":"A Matteucci","year":"2026","unstructured":"Matteucci A, Di Fusco SA, Bonanni M, et al. Comparative efficacy and safety of obicetrapib vs bempedoic acid on top of statin therapy: a network meta-analysis. J Clin Lipidol. 2026. https:\/\/doi.org\/10.1016\/j.jacl.2026.02.018.","journal-title":"J Clin Lipidol"},{"issue":"24","key":"2338_CR59","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73(24):e285\u2013350. https:\/\/doi.org\/10.1016\/j.jacc.2018.11.003.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2338_CR60","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"issue":"2","key":"2338_CR61","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","volume":"9","author":"R Chaudhary","year":"2017","unstructured":"Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017;9(2):76. https:\/\/doi.org\/10.4330\/wjc.v9.i2.76.","journal-title":"World J Cardiol"},{"key":"2338_CR62","doi-asserted-by":"publisher","unstructured":"Atherosclerosis L, Barkas F, Szarek M, et al. Efficacy of obicetrapib across the spectrum of background lipid-lowering therapies: pooled analyses of the BROADWAY and BROOKLYN randomized trials. Eur J Prev Cardiol. 2025;00:1\u20133. https:\/\/doi.org\/10.1093\/eurjpc\/zwaf788","DOI":"10.1093\/eurjpc\/zwaf788"},{"key":"2338_CR63","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212525","volume":"7","author":"CE Kosmas","year":"2018","unstructured":"Kosmas CE, Martinez I, Sourlas A, et al. High-density lipoprotein (HDL) functionality and its relevance to atherosclerotic cardiovascular disease. Drugs Context. 2018;7:212525. https:\/\/doi.org\/10.7573\/dic.212525.","journal-title":"Drugs Context."},{"key":"2338_CR64","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.774418","volume":"8","author":"JJ Lee","year":"2021","unstructured":"Lee JJ, Chi G, Fitzgerald C, et al. Cholesterol efflux capacity and its association with adverse cardiovascular events: a systematic review and meta-analysis. Front Cardiovasc Med. 2021;8:774418. https:\/\/doi.org\/10.3389\/fcvm.2021.774418.","journal-title":"Front Cardiovasc Med."},{"key":"2338_CR65","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2119\/molmed.2011.00183","volume":"18","author":"GJ Zhao","year":"2011","unstructured":"Zhao GJ, Yin K, Fu Y, Tang CK. The interaction of ApoA-I and ABCA1 triggers signal transduction pathways to mediate efflux of cellular lipids. Mol Med. 2011;18:149. https:\/\/doi.org\/10.2119\/molmed.2011.00183.","journal-title":"Mol Med"},{"issue":"1","key":"2338_CR66","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.lfs.2012.11.001","volume":"92","author":"E Naem","year":"2013","unstructured":"Naem E, Haas MJ, Wong NCW, Mooradian AD. Endoplasmic reticulum stress in HepG2 cells inhibits apolipoprotein A-I secretion. Life Sci. 2013;92(1):72\u201380. https:\/\/doi.org\/10.1016\/j.lfs.2012.11.001.","journal-title":"Life Sci"},{"issue":"SEP","key":"2338_CR67","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2015.00187","volume":"6","author":"KY Chyu","year":"2015","unstructured":"Chyu KY, Shah PK. HDL\/ApoA-1 infusion and ApoA-1 gene therapy in atherosclerosis. Front Pharmacol. 2015;6(SEP):187. https:\/\/doi.org\/10.3389\/fphar.2015.00187.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2338_CR68","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1056\/NEJMoa2511002","volume":"394","author":"AM Navar","year":"2026","unstructured":"Navar AM, Mikhailova E, Catapano AL, et al. A placebo-controlled trial of the oral PCSK9 inhibitor enlicitide. N Engl J Med. 2026;394(6):529\u201339. https:\/\/doi.org\/10.1056\/NEJMoa2511002.","journal-title":"N Engl J Med"},{"issue":"17","key":"2338_CR69","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1056\/nejmoa2400969","volume":"390","author":"CM Gibson","year":"2024","unstructured":"Gibson CM, Duffy D, Korjian S, et al. Apolipoprotein A1 infusions and cardiovascular outcomes after acute myocardial infarction. N Engl J Med. 2024;390(17):1560\u201371. https:\/\/doi.org\/10.1056\/nejmoa2400969.","journal-title":"N Engl J Med"},{"key":"2338_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2016.10.042","volume":"255","author":"HJ Kempen","year":"2016","unstructured":"Kempen HJ, Gomaraschi M, Simonelli S, et al. Persistent changes in lipoprotein lipids after a single infusion of ascending doses of MDCO-216 (apoA-IMilano\/POPC) in healthy volunteers and stable coronary artery disease patients. Atherosclerosis. 2016;255:17\u201324. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2016.10.042.","journal-title":"Atherosclerosis"},{"issue":"7","key":"2338_CR71","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/11535410-000000000-00000","volume":"70","author":"MJ Haas","year":"2010","unstructured":"Haas MJ, Mooradian AD. Therapeutic interventions to enhance apolipoprotein A-I-mediated cardioprotection. Drugs. 2010;70(7):805\u201321. https:\/\/doi.org\/10.2165\/11535410-000000000-00000.","journal-title":"Drugs"},{"issue":"11","key":"2338_CR72","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1080\/15384101.2022.2042777","volume":"21","author":"L Chen","year":"2022","unstructured":"Chen L, Zhao ZW, Zeng PH, Zhou YJ, Yin WJ. Molecular mechanisms for ABCA1-mediated cholesterol efflux. Cell Cycle. 2022;21(11):1121\u201339. https:\/\/doi.org\/10.1080\/15384101.2022.2042777.","journal-title":"Cell Cycle"},{"issue":"2","key":"2338_CR73","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1097\/MOL.0000000000000673","volume":"31","author":"LA Freeman","year":"2020","unstructured":"Freeman LA, Karathanasis SK, Remaley AT. Novel LCAT-based therapeutic approaches. Curr Opin Lipidol. 2020;31(2):71. https:\/\/doi.org\/10.1097\/MOL.0000000000000673.","journal-title":"Curr Opin Lipidol"},{"issue":"5","key":"2338_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2025.100786","volume":"66","author":"B Coleman","year":"2025","unstructured":"Coleman B, Bedi S, Hill JH, et al. Lecithin:cholesterol acyltransferase binds a discontinuous binding site on adjacent apolipoprotein A-I belts in HDL. J Lipid Res. 2025;66(5):100786. https:\/\/doi.org\/10.1016\/j.jlr.2025.100786.","journal-title":"J Lipid Res"},{"issue":"3","key":"2338_CR75","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1097\/MOL.0000000000000413","volume":"28","author":"M Hoekstra","year":"2017","unstructured":"Hoekstra M, Sorci-Thomas M. Rediscovering SR-BI: surprising new roles for the HDL receptor. Curr Opin Lipidol. 2017;28(3):255. https:\/\/doi.org\/10.1097\/MOL.0000000000000413.","journal-title":"Curr Opin Lipidol"},{"issue":"6278","key":"2338_CR76","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1126\/science.aad3517","volume":"351","author":"P Zanoni","year":"2016","unstructured":"Zanoni P, Khetarpal SA, Larach DB, et al. Rare variant in scavenger receptor BI raises HDL cholesterol and increases risk of coronary heart disease. Science. 2016;351(6278):1166\u201371. https:\/\/doi.org\/10.1126\/science.aad3517.","journal-title":"Science"},{"issue":"16","key":"2338_CR77","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/eurheartj\/ehac605","volume":"44","author":"A von Eckardstein","year":"2022","unstructured":"von Eckardstein A, Nordestgaard BG, Remaley AT, Catapano AL. High-density lipoprotein revisited: biological functions and clinical relevance. Eur Heart J. 2022;44(16):1394. https:\/\/doi.org\/10.1093\/eurheartj\/ehac605.","journal-title":"Eur Heart J"},{"issue":"2","key":"2338_CR78","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s10157-013-0857-x","volume":"18","author":"S Yamamoto","year":"2013","unstructured":"Yamamoto S, Kon V. CKD-induced dysfunction of HDL. Clin Exp Nephrol. 2013;18(2):251. https:\/\/doi.org\/10.1007\/s10157-013-0857-x.","journal-title":"Clin Exp Nephrol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02338-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02338-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:14Z","timestamp":1782196754000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02338-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2338"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02338-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"27 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael J. Chehade, Michael J. Haas, and Arshag D. Mooradian all declare that they have no conflicts of interest that would be relevant to the contents of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Data sharing is not applicable; no primary datasets were generated or analyzed in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation and publication)"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"MJC conceived and designed the study, conducted the literature search, performed data extraction and synthesis, and drafted the manuscript. MJH and ADM contributed to the formulation of the research concept and study design and provided critical intellectual input during manuscript development. All authors reviewed, revised, and approved the final version of the manuscript and agreed to be accountable for all aspects of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}